679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This real-world evidence confirms the effectiveness and safety of oral semaglutide in a diverse Mexican adult population, closely mirroring the positive outcomes observed in more controlled clinical trials. The signif…
This comprehensive network meta-analysis provides crucial evidence for guiding treatment decisions in a high-risk patient population. The findings strongly support the preferential use of SGLT2 inhibitors and GLP-1 re…
This study provides crucial mechanistic insights, demonstrating that semaglutide exerts direct hepatoprotective actions via GLP-1 receptors on intrahepatic sinusoidal endothelial cells, independent of its weight-reduc…
This commentary underscores the urgent need for a proactive public health strategy to manage the societal implications of GLP-1RA proliferation. The authors argue that without clear guidelines and public education, th…
This study provides compelling evidence that tirzepatide, a dual GLP-1 and GIP receptor agonist, offers substantial cardiovascular protection beyond its established glycemic control and weight loss benefits in patient…
This study provides compelling evidence that Tirzepatide, a dual GIP and GLP-1 receptor agonist, significantly improves cardiovascular outcomes in patients with Type 2 Diabetes and high cardiovascular risk. This posit…
This landmark study provides compelling evidence that Tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, offers substantial cardiovascular prot…
These findings are profoundly significant, as they establish Tirzepatide as a potent agent for cardiovascular risk reduction in patients with Type 2 Diabetes and existing cardiovascular disease, moving beyond its know…
This comprehensive real-world analysis provides crucial insights into the differential cardiovascular benefits of two cornerstone drug classes for Type 2 Diabetes. The findings highlight that GLP-1 RAs may be more eff…
The findings from SURPASS-CVOT establish tirzepatide as a potent therapeutic agent for reducing cardiovascular risk in patients with type 2 diabetes, offering benefits beyond its metabolic effects. This is particularl…
GLP-1 RAs represent a highly promising pharmacological approach for managing prediabetes and actively preventing its progression to type 2 diabetes. Their dual action on glucose control and weight loss addresses key p…
The widespread use of GLP-1 RAs for managing diabetes and obesity makes understanding their perioperative implications critically important for patient safety. This study directly addresses the potential for increased…
This research is crucial because it addresses a significant unmet need for effective and safe treatments for obesity and cardiovascular risk in individuals with Type 1 Diabetes. If Semaglutide proves effective in impr…
As this study is currently "NOT_YET_RECRUITING" and is scheduled to begin in 2026, no results or specific data are available at this time. The primary objective is to determine if there are significant differences in …
This Phase 1 study is a critical foundational step for advancing NNC0480-0389 as a potential combination therapy. If the drugs can be safely co-administered without adverse pharmacokinetic interactions, it significant…
This study is crucial because it seeks to uncover a novel mechanism by which semaglutide promotes weight loss, specifically through its impact on brown adipose tissue (BAT). Understanding this pathway could lead to mo…
This study holds significant promise for overweight and obese women struggling with infertility, potentially offering a novel therapeutic strategy to improve IVF success rates. If Semaglutide pre-treatment proves effe…
This diagnostic study, while listed as completed, has not yet published its specific findings regarding gastric contents in patients on semaglutide, with the official completion date set for 2025-05-31. However, the f…
This study is significant because it provides valuable real-world evidence on Semaglutide's effectiveness, complementing the data from highly controlled clinical trials. Understanding how a drug performs in diverse pa…
The MAINTAIN study addresses a critical unmet need in obesity management, offering a potential solution to the widespread problem of weight regain after discontinuing GLP-1 RAs. GFMA could provide a durable, non-pharm…
This real-world data provides crucial insights into the comparative effectiveness of two powerful drug classes for diabetic patients post-ACS. The findings suggest that while both Semaglutide and SGLT2 inhibitors offe…
This study provides compelling evidence that revisional bariatric surgery offers superior long-term weight loss and metabolic comorbidity resolution compared to semaglutide for patients experiencing recurrent weight g…
This study underscores the increasing integration of GLP-1 RAs into the clinical management pathway for patients with severe obesity and related comorbidities who are considering sleep surgery. The observed significan…
Semaglutide is currently not FDA-approved for Type 1 Diabetes, making this research critical for exploring new therapeutic avenues in a population with significant unmet medical needs. If the trial demonstrates positi…
This discovery of novel GLP-1 mimotopes represents a significant step forward in the development of new therapeutic agents for type 2 diabetes and obesity. These smaller, potentially more stable, and easier-to-manufac…
The widespread adoption of GLP-1 receptor agonists means plastic surgeons are increasingly encountering patients with significant, rapid weight loss, necessitating a paradigm shift in surgical planning. This review pr…
This study provides valuable real-world evidence, reinforcing Semaglutide's efficacy not only in achieving substantial weight loss but also in improving critical metabolic parameters and, importantly, the overall heal…
This comprehensive meta-analysis provides strong evidence that Tirzepatide, a dual GIP/GLP-1 receptor agonist, offers superior glycemic control and weight loss benefits compared to Dulaglutide, a selective GLP-1 recep…
This study provides valuable real-world insights into the comparative safety profiles of tirzepatide, semaglutide, and liraglutide, which can complement findings from controlled clinical trials. The observed differenc…
This study highlights a crucial aspect of Tirzepatide's efficacy: its ability to preserve fat-free mass during weight loss is strongly linked to enhanced glycaemic control. This finding suggests that Tirzepatide offer…
This review provides crucial, evidence-based practical guidance for clinicians navigating the complex, often challenging, management of patients with concurrent CKD and T2D. By synthesizing the latest research and off…
This study provides compelling evidence that combining GLP-1RA and SGLT2i therapies offers a powerful and potentially synergistic strategy to mitigate liver fibrosis progression in patients with MASLD and Type 2 Diabe…
This study provides compelling evidence that semaglutide is highly effective in reversing advanced MASH pathology, including significant liver fibrosis, in a robust and clinically relevant animal model. The observed i…
The findings summarized in this review suggest that PentaPeptide-5 and similar multi-receptor agonists represent a significant advancement in the treatment of obesity and type 2 diabetes. By targeting multiple metabol…
The successful demonstration of semaglutide's safety and tolerability in CFRD patients would be a significant step forward, potentially offering a novel therapeutic avenue beyond insulin. If proven safe and effective …
This multi-national trial is crucial for understanding the comparative effectiveness of two prominent classes of Type 2 Diabetes medications when added to standard metformin therapy. The findings, once published, will…
Understanding how liver function affects oral semaglutide's pharmacokinetics is crucial for dose adjustments and patient safety, especially given the widespread use of GLP-1 receptor agonists for type 2 diabetes. The …
This study holds significant promise for addressing a critical unmet medical need: effective treatment for early-onset, treatment-resistant obesity in young adults. If successful, the RESETTLE Study could establish se…
The discontinuation of GLP-1 agonists often leads to weight regain and a return of metabolic challenges, including elevated triglycerides, which are risk factors for cardiovascular disease. If RDX-002 proves effective…
This research is critically important as it will provide evidence-based guidance for managing incretin-based therapies in patients undergoing upper endoscopy, potentially enhancing patient safety and procedural effici…
This SemaGBA system dynamics model provides a crucial mechanistic understanding of how semaglutide orchestrates its effects on the gut-brain axis to promote weight loss. By simulating complex biological interactions, …
This case report highlights a rare but serious adverse event associated with tirzepatide use, particularly in individuals without pre-existing diabetes or obesity. Clinicians must be vigilant for symptoms of ketoacido…
This commentary underscores the critical importance of addressing metabolic comorbidities in inflammatory diseases like psoriatic arthritis. The hypothetical findings suggest that combining an IL-17A inhibitor with a …
These findings provide critical clinical guidance, underscoring that semaglutide's profound cardiovascular benefits are robust and complementary to, rather than dependent on, traditional antiplatelet therapy with aspi…
This research highlights the distinct advantages of metabolic bariatric surgery for improving liver health outcomes in patients with co-existing MASLD and T2D, potentially offering a more comprehensive solution for th…
This groundbreaking research underscores the potential of Semaglutide as a multifaceted therapeutic agent, extending its benefits beyond glycemic control and weight management to include significant liver protection. …
These meticulously developed guidelines are profoundly important for enhancing patient safety and optimizing long-term oral health outcomes for the rapidly expanding population of individuals prescribed semaglutide fo…